Symptomatic treatment options for Huntington's disease (guidelines of the German Neurological Society).

Saft, Carsten; Burgunder, Jean-Marc; Dose, Matthias; Jung, Hans Heinrich; Katzenschlager, Regina; Priller, Josef; Nguyen, Huu Phuc; Reetz, Kathrin; Reilmann, Ralf; Seppi, Klaus; Landwehrmeyer, Georg Bernhard (2023). Symptomatic treatment options for Huntington's disease (guidelines of the German Neurological Society). Neurological research and practice, 5(1), p. 61. BioMed Central 10.1186/s42466-023-00285-1

Preview

Text Saft__2023__Symptomatic_treatment_options.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (956kB) | Preview

INTRODUCTION

Ameliorating symptoms and signs of Huntington's disease (HD) is essential to care but can be challenging and hard to achieve. The pharmacological treatment of motor signs (e.g. chorea) may favorably or unfavorably impact other facets of the disease phenotype (such as mood and cognition). Similarly, pharmacotherapy for behavioral issues may modify the motor phenotype. Sometimes synergistic effects can be achieved. In patients undergoing pragmatic polypharmacological therapy, emerging complaints may stem from the employed medications' side effects, a possibility that needs to be considered. It is recommended to clearly and precisely delineate the targeted signs and symptoms (e.g., chorea, myoclonus, bradykinesia, Parkinsonism, or dystonia). Evidence from randomized controlled trials (RCTs) is limited. Therefore, the guidelines prepared for the German Neurological Society (DGN) for German-speaking countries intentionally extend beyond evidence from RCTs and aim to synthesize evidence from RCTs and recommendations of experienced clinicians.

RECOMMENDATIONS

First-line treatment for chorea is critically discussed, and a preference in prescription practice for using tiapride instead of tetrabenazine is noted. In severe chorea, combining two antidopaminergic drugs with a postsynaptic (e.g., tiapride) and presynaptic mode of action (e.g., tetrabenazine) is discussed as a potentially helpful strategy. Sedative side effects of both classes of compounds can be used to improve sleep if the highest dosage of the day is given at night. Risperidone, in some cases, may ameliorate irritability but also chorea and sleep disorders. Olanzapine can be helpful in the treatment of weight loss and chorea, and quetiapine as a mood stabilizer with an antidepressant effect.

CONCLUSIONS

Since most HD patients simultaneously suffer from distinct motor signs and distinct psychiatric/behavioral symptoms, treatment should be individually adapted.

Interest & Impact

Downloads

0 since deposited on 04 Jan 2024
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item